View profile

FarmaKology Newsletter - Issue #57



September 1 · Issue #57 · View online
FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+7878 Subscribers ) !

Today's Startup
Diagnosia is a new kind of medical software company and we believe that it’s time to truly support physicians in the their daily clinical decisions, at the point of care, with most intuitive, simplest interfaces.Diagnosia is Austria’s most used doctor app and and fully integrated in over 65 hospitals across Austria, Germany and Switzerland.We genuinely believe in making medicine simple through software.
Isofol Medical , has announced today that the company has further strengthened its position in the second largest market for treatment of mCRC by obtaining two new patent grants for arfolitixorin in Japan. One relates to the preparation process of the drug for injection and one relates to the dosage regimens, including those applied in the ongoing global Phase III study AGENT. Together with the already granted Active Substance Patent (API), these two patents will ensure a strong and extended patent protection for the important future Japanese market until 2038.
WPD Pharmaceuticals Inc.a clinical stage pharmaceutical company, is excited to announce that a recently published study confirms the high therapeutic potential of IL-13RA2- and EphA2 receptor-targeted cytotoxins in the WPD101 drug candidate. The study found the combination of these cytotoxins as a highly effective anticancer therapy in dogs with spontaneous intracranial gliomas.
Gilead Sciences, Inc. today announced an agreement with Jounce Therapeutics, Inc. , a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively license its JTX-1811 program.
Novavax, Inc. , a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, Novavax’ COVID-19 vaccine.
Research & Study
Identifying Barriers To And Developing Opportunities For Rotavirus Vaccination PeerVoice Clinical Pharmacology Audio podcast
Job Opportunities
Upcoming Webinar
Antibiotics, Antivirals, and Vaccines
Did you enjoy this issue?
If you don't want these updates anymore, please unsubscribe here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue